Shares of the AdvisorShares Pure US Cannabis ETF (MSOS) have climbed to their highest levels of 2026, and the timing isn't coincidental. Investors are positioning ahead of a federal rescheduling hearing later this month, and Trulieve's move onto the New York Stock Exchange has given the trade a fresh narrative. As of May 31, MSOS posted a 103.7% one-year NAV return, well ahead of the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%. That kind of outperformance doesn't happen without a catalyst, and here the catalyst is regulatory.
The mechanics matter more than the headline number. Multi-state operators have spent years building out compliance infrastructure - seed-to-sale tracking, METRC reporting, batch-level lab testing - while absorbing a federal tax code that treats them like traffickers under 280E. Every operator running compliant packaging lines and point-of-sale terminals in a limited-license state knows the drill: a huge share of revenue disappears into taxes that ordinary businesses never pay, because cannabis companies can't deduct standard operating expenses. That's precisely why the April move to reclassify state-licensed medical marijuana into Schedule III landed with such force. It didn't just shift a scheduling number on paper; it opened the door for licensed medical operators to deduct payroll, rent and interest like any other regulated business. Operators managing multi-state footprints, and even smaller single-state license holders relying on tools like a cannabis seed to sale erp maine platform to keep inventory and tax reporting aligned, are watching this rule change closely, because tax treatment shapes margin in ways that pricing decisions never can. cannabis seed to sale erp maine
Trulieve's NYSE listing, trading under TRLV, reflects that shift in real terms. The company restructured to separate medical cannabis operations from its adult-use business specifically to qualify for a senior exchange listing - not a small maneuver, and one that other multi-state operators are almost certainly studying as a template.
Why the June Hearing Carries Weight
The administrative hearing scheduled for June 29, expected to run through mid-July, will examine whether broader cannabis products - including adult-use, not just medical - should move to Schedule III. That's a meaningfully bigger question than the April action addressed. Adult-use retailers, who currently get none of the tax relief extended to medical-only operators, have the most to gain or lose depending on the outcome. For a dispensary running thin margins after excise tax, wholesale compression and inventory shrinkage, the difference between deductible and non-deductible operating expenses can determine whether a store stays open.
Roth Capital's characterization of the April order as "extremely favorable" points to the mechanism at work: easier access to capital markets, improved banking relationships, and a credible path toward uplisting for companies still stuck on over-the-counter exchanges. Cresco Labs' new $50 million revolving credit facility from Needham Bank is an early example of what that access looks like in practice - non-dilutive financing that wasn't readily available to plant-touching operators a few years back.
What Operators and Investors Should Watch
Enthusiasm is running ahead of certainty. A hearing isn't a rule change, and administrative proceedings can stretch, stall or narrow in scope. For operators, the sensible move is to keep compliance logs, COAs and financial reporting airtight regardless of the outcome, since federal attention - favorable or not - tends to invite closer scrutiny of state-level licensing and tax compliance. For retail investors chasing upside across MSOS holdings, the wider spread between names like Verano and Trulieve suggests the market hasn't settled on a single winner. That uncertainty is the story here, not any one company's stock chart.
